Change in Neurocognitive Performance Among Patients With Non-Hodgkin’s Lymphoma in the First Year After CAR T-Cell Therapy

This study examined changes in neurocognitive performance in the first year after CAR-T-cell therapy for non-Hodgkin’s lymphoma. Putative risk factors for worsening neurocognitive performance (e.g., neurotoxicity, CRS) were also explored. CAR T-cell therapy recipients reported transient or persistent deterioration in several cognitive domains, although changes were small. These findings may be useful when educating future patients on what to expect when receiving CAR T-cell therapy.